UNLABELLED: There are many reports that cross-linking antibodies (Abs) bound to the surface of B-lymphoma cells can induce apoptosis and/or cell death, especially with anti-CD20 Abs. This study was intended to extend our understanding of these effects. To determine if CD20 is a unique target in this respect, or whether Abs to other antigens would have similar effects, six Abs were tested, with and without cross-linking with a secondary Ab, on three target cell lines. We utilized assays that distinguish between apoptotic, dead, and viable cells. Two assays were used: Annexin V plus propidium iodide, and JC-1 plus SYTOX green (Molecular Probes, Eugene, OR). Most of the Abs tested induced a low level of apoptosis and cell death in Ramos cells, but not in the other two cell lines (Raji and RL). In general, the level of toxicity was correlated with the level of antigen expression, with Abs to high-density antigens having the strongest effects. However, since the majority of Ramos cells continued to multiply, it is questionable whether toxicity at this level can provide a significant clinical benefit. Unexpectedly, there was also a population of cells that stained weakly with Annexin V. These cells were distinct from classical apoptotic cells, and appeared to belong to the viable cell population. In these cells, Annexin V stained the region of the Ab cap, in contrast to the ringed staining of classical apoptotic cells. IN CONCLUSION: 1) Low-level induction of apoptosis was not unique for anti-CD20 Abs, but occurred similarly with other Abs, and 2) results of Annexin V staining experiments may need to be reevaluated. Further studies are required to explain why Annexin V binding sites are exposed in the region of an Ab cap.
UNLABELLED: There are many reports that cross-linking antibodies (Abs) bound to the surface of B-lymphoma cells can induce apoptosis and/or cell death, especially with anti-CD20 Abs. This study was intended to extend our understanding of these effects. To determine if CD20 is a unique target in this respect, or whether Abs to other antigens would have similar effects, six Abs were tested, with and without cross-linking with a secondary Ab, on three target cell lines. We utilized assays that distinguish between apoptotic, dead, and viable cells. Two assays were used: Annexin V plus propidium iodide, and JC-1 plus SYTOX green (Molecular Probes, Eugene, OR). Most of the Abs tested induced a low level of apoptosis and cell death in Ramos cells, but not in the other two cell lines (Raji and RL). In general, the level of toxicity was correlated with the level of antigen expression, with Abs to high-density antigens having the strongest effects. However, since the majority of Ramos cells continued to multiply, it is questionable whether toxicity at this level can provide a significant clinical benefit. Unexpectedly, there was also a population of cells that stained weakly with Annexin V. These cells were distinct from classical apoptotic cells, and appeared to belong to the viable cell population. In these cells, Annexin V stained the region of the Ab cap, in contrast to the ringed staining of classical apoptotic cells. IN CONCLUSION: 1) Low-level induction of apoptosis was not unique for anti-CD20 Abs, but occurred similarly with other Abs, and 2) results of Annexin V staining experiments may need to be reevaluated. Further studies are required to explain why Annexin V binding sites are exposed in the region of an Ab cap.
Authors: Kathy Miller; Gloria Meng; Jun Liu; Amy Hurst; Vanessa Hsei; Wai-Lee Wong; Rene Ekert; David Lawrence; Steven Sherwood; Laura DeForge; Jacques Gaudreault; Gilbert Keller; Mark Sliwkowski; Avi Ashkenazi; Leonard Presta Journal: J Immunol Date: 2003-05-01 Impact factor: 5.422
Authors: H T Claude Chan; David Hughes; Ruth R French; Alison L Tutt; Claire A Walshe; Jessica L Teeling; Martin J Glennie; Mark S Cragg Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701
Authors: Pina M Cardarelli; Maire Quinn; Dana Buckman; Yu Fang; David Colcher; David J King; Christopher Bebbington; Geoffrey Yarranton Journal: Cancer Immunol Immunother Date: 2001-12-18 Impact factor: 6.968
Authors: Ali R Jazirehi; Xiao-Hu Gan; Sven De Vos; Christos Emmanouilides; Benjamin Bonavida Journal: Mol Cancer Ther Date: 2003-11 Impact factor: 6.261
Authors: Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren Journal: Immunol Rev Date: 2016-03 Impact factor: 12.988
Authors: Jacob L Goldberg; Fariba Navid; Jacqueline A Hank; Amy K Erbe; Victor Santana; Jacek Gan; Fenna de Bie; Amal M Javaid; Anna Hoefges; Michael Merdler; Lakeesha Carmichael; KyungMann Kim; Michael W Bishop; Michael M Meager; Steven D Gillies; Janardan P Pandey; Paul M Sondel Journal: J Immunother Cancer Date: 2020-03 Impact factor: 13.751